Lv1
84 积分 2025-03-05 加入
Survival with Osimertinib plus Chemotherapy in EGFR -Mutated Advanced NSCLC
2个月前
已完结
20 years since the approval of first EGFR-TKI, gefitinib: Insight and foresight
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Unresectable stage III non-small-cell lung cancer: state of the art and challenges
2个月前
已完结
The changing treatment landscape of EGFR-mutant non-small-cell lung cancer
2个月前
已完结
Navigating the landscape of EGFR TKI resistance in EGFR-mutant NSCLC — mechanisms and evolving treatment approaches
2个月前
已完结
Acquired resistance mechanisms to osimertinib: The constant battle
2个月前
已完结
Pancreatic cancer
2个月前
已完结
The Humira patent thicket, the Noerr–Pennington doctrine and antitrust’s patent problem
3个月前
已完结
Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial
4个月前
已完结
皖公网安备34019202002308
